Ye J, Chen Z, Zhang C, Xie R, Chen H, Ren P
BMC Cancer. 2025; 25(1):218.
PMID: 39920663
PMC: 11806719.
DOI: 10.1186/s12885-025-13607-0.
Wang L, Li P, Gong S, Pang L, Li M, Zhang C
Heliyon. 2025; 11(1):e41600.
PMID: 39866451
PMC: 11759551.
DOI: 10.1016/j.heliyon.2024.e41600.
Teixeira C, Viamonte B, Graca L, Marques H, Rego I, Ribeiro M
Cureus. 2025; 16(12):e75935.
PMID: 39830568
PMC: 11740196.
DOI: 10.7759/cureus.75935.
Lederer A, Gorrissen N, Nguyen T, Kreutz C, Rasel H, Bartsch F
J Transl Med. 2025; 23(1):34.
PMID: 39789543
PMC: 11716211.
DOI: 10.1186/s12967-024-06012-x.
Porro N, Spinola-Lasso E, Pastore M, Caligiuri A, Di Tommaso L, Marra F
Cancers (Basel). 2025; 16(24.
PMID: 39766138
PMC: 11674836.
DOI: 10.3390/cancers16244239.
Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes.
da Fonseca L, Izquierdo-Sanchez L, Hashizume P, Carlino Y, Baca E, Zambrano C
Lancet Reg Health Am. 2024; 40:100952.
PMID: 39655285
PMC: 11626722.
DOI: 10.1016/j.lana.2024.100952.
Epidemiology of biliary tract cancer in China: A narrative review.
Zhou J, Tan G, Zhang L, Xie G, Chen W, Zhang X
Chin J Cancer Res. 2024; 36(5):474-488.
PMID: 39539810
PMC: 11555199.
DOI: 10.21147/j.issn.1000-9604.2024.05.02.
Personalized treatment of perihilar cholangiocarcinoma based on tumor genetic and molecular characteristics.
Tang H, Wang M, Liu X, Jiao Y
World J Gastrointest Surg. 2024; 16(9):2769-2773.
PMID: 39351571
PMC: 11438824.
DOI: 10.4240/wjgs.v16.i9.2769.
Metformin dampens the progression of cholangiofibrosis induced by thioacetamide using deep learning.
Li C, Deng Y, Pan Y, Liao X, Xie H, Xue X
Heliyon. 2024; 10(18):e37347.
PMID: 39309781
PMC: 11416239.
DOI: 10.1016/j.heliyon.2024.e37347.
Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1/ARID1A mutations: a case report with an unexpected response.
Daugan C, Boidot R, Ghiringhelli F, Borg C, Vienot A
Ther Adv Med Oncol. 2024; 16:17588359241271793.
PMID: 39281970
PMC: 11401142.
DOI: 10.1177/17588359241271793.
Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.
Porreca V, Barbagallo C, Corbella E, Peres M, Stella M, Mignogna G
Cancers (Basel). 2024; 16(16).
PMID: 39199659
PMC: 11352949.
DOI: 10.3390/cancers16162889.
Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions.
Zhang G, Li J, Li G, Zhang J, Yang Z, Yang L
Clin Exp Med. 2024; 24(1):193.
PMID: 39141161
PMC: 11324771.
DOI: 10.1007/s10238-024-01460-7.
Promotion of perineural invasion of cholangiocarcinoma by Schwann cells via nerve growth factor.
Qian X, Liu E, Zhang C, Feng R, Tran N, Zhai W
J Gastrointest Oncol. 2024; 15(3):1198-1213.
PMID: 38989424
PMC: 11231841.
DOI: 10.21037/jgo-24-309.
Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.
Choi J, Thung S
Cancers (Basel). 2024; 16(8).
PMID: 38672619
PMC: 11048541.
DOI: 10.3390/cancers16081537.
Clinical significance of small extracellular vesicles in cholangiocarcinoma.
Wang J, Shi R, Yin Y, Luo H, Cao Y, Lyu Y
Front Oncol. 2024; 14:1334592.
PMID: 38665948
PMC: 11043544.
DOI: 10.3389/fonc.2024.1334592.
Causal roles of gut microbiota in cholangiocarcinoma etiology suggested by genetic study.
Chen Z, Ding C, Chen K, Gu Y, Lu C, Li Q
World J Gastrointest Oncol. 2024; 16(4):1319-1333.
PMID: 38660662
PMC: 11037042.
DOI: 10.4251/wjgo.v16.i4.1319.
Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J, Ma X, Xu F, Yan Y, Chen W
Pharm Biol. 2024; 62(1):314-325.
PMID: 38571483
PMC: 10997361.
DOI: 10.1080/13880209.2024.2331060.
RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination.
Zhang C, Wang Y, Wu G, Sun N, Bai H, Li X
Biol Direct. 2024; 19(1):16.
PMID: 38395908
PMC: 10885515.
DOI: 10.1186/s13062-024-00453-6.
Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review.
Liang Y, Hu L, Wu H, Yin T, Zhang J
Front Oncol. 2024; 14:1292319.
PMID: 38327739
PMC: 10848247.
DOI: 10.3389/fonc.2024.1292319.
Cellular Senescence in Liver Cancer: How Dying Cells Become "Zombie" Enemies.
Gazzillo A, Volponi C, Soldani C, Polidoro M, Franceschini B, Lleo A
Biomedicines. 2024; 12(1).
PMID: 38275386
PMC: 10813254.
DOI: 10.3390/biomedicines12010026.